Trial reportAntimicrobial agents and chemotherapy2018
Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.
Trial report in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.Journal of clinical pharmacology · 2021Trial
- Trial
- Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for Tuberculous Meningitis.The Journal of infectious diseases · 2026Article
- Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistantAntimicrobial agents and chemotherapy · 2026Article
- Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.Contemporary clinical trials · 2025Article
- Bedaquiline Delivery Innovations: A Review on Advancing MDR-TB Treatment Strategies.Recent advances in anti-infective drug discovery · 2025Review
- Phenotypic and genotypic analysis of drug resistance in M. tuberculosis isolates in Gansu, China.PloS one · 2024Article
- Development and Validation of a Novel UHPLC-MS/MS Method for the Quantification of Plinabulin in Plasma and Its Application in a Pharmacokinetic Study with Leukopenic Rats.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients.Frontiers in pharmacology · 2023Article
- Antibiotics in the pipeline: a literature review (2017-2020).Infection · 2022Review
- Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.Antimicrobial agents and chemotherapy · 2022Article
- A Scoping Review of the Clinical Pharmacokinetics of Bedaquiline.Clinical pharmacokinetics · 2022Article
- Analysis of the Research Hotspot of Drug Treatment of Tuberculosis: A Bibliometric Based on the Top 50 Cited Literatures.BioMed research international · 2022Review
- DifferentialAntimicrobial agents and chemotherapy · 2021Article
- Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?Journal of the International AIDS Society · 2019Article
- Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Bedaquiline is a diarylquinoline that specifically inhibits mycobacterial ATP synthase. Bedaquiline has been used to effectively treat tuberculosis (TB) caused by drug-susceptible and drug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.